Fig. 3: Analysis of KRAS and TP53 mutation types in HD-ICI.
From: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
a Distribution of the mutations in KRAS. b Distribution of the mutations in TP53. c Univariate analysis of OS comparing tumours having specific KRAS mutations with KRASwt tumours, of the tumour having specific TP53 mutations with TP53wt tumours, and of tumours having specific types of KRAS/TP53 co-mutation with the basket of not double-mutated tumours. *without G12C mutation
